Treating ADHD: What Works Best by Age, According to the Evidence

Treating ADHD rests on two evidence-backed approaches, medication and behavior therapy, with the mix set by age. The CDC, summarizing American Academy of Pediatrics (AAP) recommendations, lists parent training in behavior management as first-line treatment for children younger than 6 and medication combined with behavior therapy for children 6 and older^[1].

A 2024 systematic review for the AAP pooled 312 studies of treatments for children and teens and found that medications had the strongest evidence base, although they were associated with adverse events^[2]. For how many children and adults have the condition, see the ADHD statistics page.

Adults have a separate evidence base. A 2025 network meta-analysis of 113 randomized trials in adults found that only stimulants and atomoxetine reduced core symptoms on both self-rated and clinician-rated scales^[3].

Many people with a diagnosis receive neither form of care. In 2023, 36.5% of U.S. adults with current ADHD were receiving no treatment^[4].

Children under 6

For preschoolers, the CDC notes that parent training in behavior management has been shown to work as well as medication, that young children have more side effects from ADHD medications than older children, and that long-term medication effects in this age group have not been well studied^[1]. Experts recommend medication for children under 6 only after behavior therapy has been tried first^[1].

FDA-approved ADHD medications on the market were tested in children 6 and older, and the FDA has asked for clinical trials that include children as young as 4 and 5^[6].

Ages 6 to 12

From age 6, the recommendation shifts to medication plus behavior therapy, with parent training in behavior management continuing through age 12^[1]. Behavioral classroom interventions, peer-focused behavioral interventions and organizational skills training are also considered effective, and the CDC notes they are often most effective when used together^[1].

In the 2024 AAP review, stimulants as a class improved ADHD symptom severity with a standardized mean difference (SMD) of −0.88, rated high strength of evidence^[2]. Nonstimulants as a class also improved symptoms (SMD −0.52, high strength of evidence), and indirect comparisons favored stimulants over nonstimulants^[2].

The FDA has approved two medication types for ADHD: stimulants, which contain forms of methylphenidate or amphetamine, and four nonstimulants, atomoxetine, guanfacine, clonidine and viloxazine^[6]. The ADHD meds guide covers individual drugs and side effects.

Adolescents

For teens, the recommendation keeps medication alongside behavior therapy and training designed for adolescents rather than parent training alone^[1]. The evidence is thinner here: of 19 parent-support studies in the AAP review, only 3 included teenagers^[2]. Age-specific figures are on the ADHD in adolescents page.

The most comprehensive synthesis of adult ADHD treatment, by its authors’ description, is a 2025 component network meta-analysis in The Lancet Psychiatry covering 113 randomized trials and 14,887 adults^[3]. It pooled medication, psychological therapy and neurostimulation trials and measured core symptoms at the point closest to 12 weeks^[3].

Stimulants and atomoxetine reduced core ADHD symptoms on both self-reported and clinician-reported scales^[3]. Cognitive behavioral therapy, cognitive remediation, mindfulness, psychoeducation and transcranial direct current stimulation (tDCS) beat placebo only on clinician-reported measures^[3].

Acceptability, measured by all-cause dropout, was similar to placebo for every treatment component except atomoxetine and guanfacine, which had lower acceptability^[3]. The authors also found that ADHD medications did not improve quality of life and that longer-term evidence is underinvestigated^[3].

U.S. adult care is split. In a 2023 national survey, 35.2% of adults with ADHD were receiving both medication and counseling or behavioral treatment, 50.4% had been prescribed ADHD medication in the past year, and 36.5% were receiving no treatment^[4]. More than half (55.9%) had been diagnosed in adulthood^[4].

Psychotherapy trials in adults are covered in CBT for ADHD, and population data are on the ADHD in adults page.

Several non-drug treatments have trial support, though most show smaller or less certain effects than medication. NIMH lists cognitive behavioral therapy, parent training and school interventions among standard psychosocial treatments, and neurofeedback, cognitive training, mindfulness and neuromodulation among newer approaches^[7].

In the 2024 AAP review, parent support programs, neurofeedback and cognitive training each improved ADHD symptoms in children, all with low strength of evidence^[2]. School interventions did not significantly improve symptoms across 5 pooled studies, although most individual studies reported better academic performance^[2].

How parent training and classroom programs are delivered is covered in the behavior therapy for ADHD guide.

Devices

In April 2019, the FDA authorized the Monarch external trigeminal nerve stimulation (eTNS) system, the first non-drug ADHD treatment granted marketing authorization, for children ages 7 to 12 who are not taking ADHD medication^[8]. In its 62-child trial, average clinician-rated ADHD-RS scores fell from 34.1 to 23.4 points over 4 weeks with the device, compared with 33.7 to 27.5 points with a placebo device^[8].

Diet, supplements and alternative therapies

Across 23 pooled studies, nutrition approaches as a group improved ADHD symptoms (SMD −0.39), but the reviewers did not identify any specific supplement that consistently improved outcomes, including omega-3 fatty acids^[2]. Acupuncture, homeopathy and hippotherapy did not significantly improve ADHD symptoms across 3 pooled studies^[2].

The CDC describes nutritious food, plenty of physical activity and sufficient sleep as important habits that can help keep ADHD symptoms from getting worse^[1].

The AAP recommends the combination for school-age children, but pooled trials have not shown a consistent added benefit on core symptoms^[1][2]. The 2024 AAP review identified 11 studies that combined medication with youth-directed psychosocial treatment, most of which compared the combination with medication alone^[2].

Across 7 of those studies, combined therapy did not significantly improve ADHD symptoms (SMD −0.36, low strength of evidence), and results varied widely between studies^[2]. The reviewers noted that both approaches worked as monotherapies and that few combinations have been studied^[2].

Those pooled results cover core symptoms only. Co-occurring conditions are common: nearly 78% of children with ADHD had at least one other condition, almost half had a behavior or conduct problem, and about 4 in 10 had anxiety^[9].

By parent report, 53.2% of U.S. children aged 3 to 17 with current ADHD were taking ADHD medication in 2024, down from 57.7% in 2016^[5]. The share who had received behavioral treatment in the past year was 46.1% in 2024, compared with 45.4% in 2016^[5].

In 2022, about 30% of children with ADHD received neither medication nor behavior treatment, up from 23% in 2016, and about 32% received both^[9]. Across states, the share receiving any ADHD treatment ranged from 58% to 80% in 2020 to 2023^[9].

Among U.S. adults with current ADHD in 2023, 33.4% had taken a stimulant and 5.9% a nonstimulant in the past year^[4]. Of those taking stimulants, 71.5% had difficulty filling a prescription because the medication was unavailable^[4]. Almost half (46.0%) had ever used telehealth for ADHD care^[4].

Prescription trends are tracked in ADHD medication statistics, and diagnosis rates for younger ages are on the ADHD in children page.

Long-term data are the main gap. The adult network meta-analysis measured outcomes near 12 weeks and concluded that longer-term evidence is underinvestigated^[3].

Head-to-head trials are rare. The 2024 AAP review found limited evidence from studies directly comparing treatments, and only 1 study compared amphetamine with methylphenidate head to head^[2].

Function lags behind symptoms. Stimulants improved symptom severity in children but did not significantly improve functional impairment in the 4 pooled studies that measured it^[2]. In adults, medications did not improve quality of life^[3].

The youngest children are understudied. Medications on the market were tested in children 6 and older, and long-term effects of ADHD medication in preschoolers have not been well studied^[6][1].

Screening and diagnosis, which come before any treatment decision, are covered in the ADHD test guide.